Conversion of CD95 (Fas) type II into type I signaling by sub-lethal doses of cycloheximide (2008)
- Authors:
- USP affiliated authors: CASTRO, FABÍOLA ATTIÉ DE - FCFRP ; MENDES, JOAO GUSTAVO PESSINI AMARANTE - ICB
- Unidades: FCFRP; ICB
- DOI: 10.1016/j.yexcr.2007.11.003
- Subjects: APOPTOSE; IMUNOPATOLOGIA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Experimental Cell Research
- ISSN: 0014-4827
- Volume/Número/Paginação/Ano: v. 314, p. 554-563, 2008
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
- Licença: other-oa
-
ABNT
BRUMATTI, G. et al. Conversion of CD95 (Fas) type II into type I signaling by sub-lethal doses of cycloheximide. Experimental Cell Research, v. 314, p. 554-563, 2008Tradução . . Disponível em: https://doi.org/10.1016/j.yexcr.2007.11.003. Acesso em: 19 set. 2024. -
APA
Brumatti, G., Yon, M., Castro, F. A. de, Bueno da Silva, A. E. B., Jacysyn, J. F., Brunner, T., & Amarante-Mendes, J. G. P. (2008). Conversion of CD95 (Fas) type II into type I signaling by sub-lethal doses of cycloheximide. Experimental Cell Research, 314, 554-563. doi:10.1016/j.yexcr.2007.11.003 -
NLM
Brumatti G, Yon M, Castro FA de, Bueno da Silva AEB, Jacysyn JF, Brunner T, Amarante-Mendes JGP. Conversion of CD95 (Fas) type II into type I signaling by sub-lethal doses of cycloheximide [Internet]. Experimental Cell Research. 2008 ; 314 554-563.[citado 2024 set. 19 ] Available from: https://doi.org/10.1016/j.yexcr.2007.11.003 -
Vancouver
Brumatti G, Yon M, Castro FA de, Bueno da Silva AEB, Jacysyn JF, Brunner T, Amarante-Mendes JGP. Conversion of CD95 (Fas) type II into type I signaling by sub-lethal doses of cycloheximide [Internet]. Experimental Cell Research. 2008 ; 314 554-563.[citado 2024 set. 19 ] Available from: https://doi.org/10.1016/j.yexcr.2007.11.003 - Development and characterization of murine models of T lymphoma to investigate the impact of oncogene expression
- T lymphoma murine models to study the impact of ectopic expression of anti-apoptotic oncogenes
- Cosmomycin D, an anthracycline more potent than Doxorubicin for induction of tumor cell death, synergize with imatinib mesilate to induce apoptosis in Bcr-Abl-positive cells
- Study of pro and anti-apoptotic genes to understand the resistance of apoptosis mediated by Bcr-Abl
- BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia
- Indoleamine 2,3-dioxygenase expression in chronic myelogenous leukemia patients: association with disease progression
- Apoptotic genes expression in head and neck squamous cell carcinoma (HNSCC) patients
- Expression of pro-apoptotic bid and bik genes is decreased in chronic myeloid leukemia and low levels of bik MRNA are associated with lack of response to imatinib treatment
- BCR–ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients
- Down regulation of Hematopoietic SH2 domain containing (HSH2D) in the progression of the chronic myelogenous leukemia
Informações sobre o DOI: 10.1016/j.yexcr.2007.11.003 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
